Fluoroquinolone Litigation Moving Forward
Proceedings are moving forward in litigation involving fluoroquinolone drugs such as Avelox, Levaquin and others. Several issues have been discussed, including a case management plan and the scheduling of the first trial dates. Plaintiffs in these cases are alleging drug manufacturers did not properly warn doctors and patients about the potential for health complications such as nerve damage.
Peripheral Neuropathy Dangers
Fluoroquinolones are a group of powerful antibiotics that have been linked to peripheral neuropathy and nerve damage. Peripheral neuropathy is a condition where nerves in the feet, arms, hands and legs are damaged to the point where numbness, weakness and other symptoms occur. In many instances, the damage attributed to fluoroquinolones has been permanent. Although fluoroquinolones are designed to treat severe infections, they are commonly prescribed for less serious issues such as sinus and urinary tract infections.
The U.S. Food and Drug Administration (FDA) ordered manufacturers of these drugs to change their product labels to not only warn users of the potentially rapid onset of symptoms, but to also warn that those symptoms could be irreversible. An FDA panel recently stated that the benefits of fluoroquinolones to treat relatively minor infections are outweighed by the potential risks.
Nearly 400 fluoroquinolone peripheral neuropathy lawsuits are pending in the U.S. District Court, District of Minnesota. These new developments are an indication that an announcement of the first trial dates may be made soon.